Find Clinical Trial

An open-label, randomised, non-comparative phase 2 study evaluating S 95005 (TAS-102) plus bevacizumab and capecitabine plus bevacizumab in patients with previously untreated metastatic COlorectal cancer who are non-eligible for intensive therapy – TASCO1 study


← Back
Study Phase

Phase 2

Therapeutic Area

Cancers

IndicationSolid tumors
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active substance/
Medical device

TIPIRACIL, TRIFLURIDINE,
S095005

Active Substance CodeS095005
Protocol CodeCL2-95005-002
EudraCT Code2015-004544-18
NCT CodeNCT02743221


Documents and links

First lay summary READ MORE
Second lay summary READ MORE
First results summary READ MORE
Second results summary READ MORE




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2022 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility